RTS,S/AS02A疟疾疫苗不诱导寄生虫CSP T细胞表位选择,减少感染的多重性。

PLoS clinical trials Pub Date : 2006-05-01 Epub Date: 2006-05-19 DOI:10.1371/journal.pctr.0010005
Sonia Enosse, Carlota Dobaño, Diana Quelhas, John J Aponte, Marc Lievens, Amanda Leach, Jahit Sacarlal, Brian Greenwood, Jessica Milman, Filip Dubovsky, Joe Cohen, Ricardo Thompson, W Ripley Ballou, Pedro L Alonso, David J Conway, Colin J Sutherland
{"title":"RTS,S/AS02A疟疾疫苗不诱导寄生虫CSP T细胞表位选择,减少感染的多重性。","authors":"Sonia Enosse,&nbsp;Carlota Dobaño,&nbsp;Diana Quelhas,&nbsp;John J Aponte,&nbsp;Marc Lievens,&nbsp;Amanda Leach,&nbsp;Jahit Sacarlal,&nbsp;Brian Greenwood,&nbsp;Jessica Milman,&nbsp;Filip Dubovsky,&nbsp;Joe Cohen,&nbsp;Ricardo Thompson,&nbsp;W Ripley Ballou,&nbsp;Pedro L Alonso,&nbsp;David J Conway,&nbsp;Colin J Sutherland","doi":"10.1371/journal.pctr.0010005","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes.</p><p><strong>Design: </strong>P. falciparum DNA from isolates collected during the trial was used for genotype studies.</p><p><strong>Setting: </strong>The main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004.</p><p><strong>Participants: </strong>Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection.</p><p><strong>Outcome: </strong>Divergence of DNA sequence encoding the CSP T cell-epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined.</p><p><strong>Results: </strong>We found no evidence that parasite genotypes from children in the RTS,S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 (survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, (p = 0.035, p = 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p = 0.478).</p><p><strong>Conclusions: </strong>RTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections.</p>","PeriodicalId":87416,"journal":{"name":"PLoS clinical trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2006-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1371/journal.pctr.0010005","citationCount":"74","resultStr":"{\"title\":\"RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.\",\"authors\":\"Sonia Enosse,&nbsp;Carlota Dobaño,&nbsp;Diana Quelhas,&nbsp;John J Aponte,&nbsp;Marc Lievens,&nbsp;Amanda Leach,&nbsp;Jahit Sacarlal,&nbsp;Brian Greenwood,&nbsp;Jessica Milman,&nbsp;Filip Dubovsky,&nbsp;Joe Cohen,&nbsp;Ricardo Thompson,&nbsp;W Ripley Ballou,&nbsp;Pedro L Alonso,&nbsp;David J Conway,&nbsp;Colin J Sutherland\",\"doi\":\"10.1371/journal.pctr.0010005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes.</p><p><strong>Design: </strong>P. falciparum DNA from isolates collected during the trial was used for genotype studies.</p><p><strong>Setting: </strong>The main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004.</p><p><strong>Participants: </strong>Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection.</p><p><strong>Outcome: </strong>Divergence of DNA sequence encoding the CSP T cell-epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined.</p><p><strong>Results: </strong>We found no evidence that parasite genotypes from children in the RTS,S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 (survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, (p = 0.035, p = 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p = 0.478).</p><p><strong>Conclusions: </strong>RTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections.</p>\",\"PeriodicalId\":87416,\"journal\":{\"name\":\"PLoS clinical trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1371/journal.pctr.0010005\",\"citationCount\":\"74\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pctr.0010005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2006/5/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1371/journal.pctr.0010005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2006/5/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 74

摘要

目的:候选疟疾疫苗RTS,S/AS02A是一种含有恶性疟原虫环孢子子蛋白(CSP)部分序列的重组蛋白,与乙型肝炎表面抗原连接,在专有佐剂系统AS02A中配制。最近在莫桑比克南部对5岁以下儿童进行的一项试验显示,该疫苗对感染和临床疾病都有显著和持续的疗效。在主要试验的后续研究中,对试验中发现的突破性感染进行了检查,以确定csp序列的分布是否受到疫苗的影响,并测量感染寄生虫基因型的多样性。设计:试验期间收集的恶性疟原虫分离株DNA用于基因型研究。环境:主要试验于2003年4月至2004年5月期间在莫桑比克马普托省的曼希帕拉区进行。参与者:来自主要试验的两个队列的儿童提供的寄生虫分离物如下:队列1因临床疟疾住院的儿童;研究月8.5时横断面调查中寄生虫阳性的队列1儿童;在随访期间,通过主动检测感染,队列2的儿童被确定为寄生虫阳性。结果:在521株分离株中测定了编码CSP T细胞表位区序列的DNA序列与疫苗序列的差异。不同恶性疟原虫基因型的数量也被确定。结果:我们没有发现RTS,S/AS02A组儿童的寄生虫基因型比接种对照疫苗的儿童更分化的证据。在队列1(研究月8.5时的调查)和队列2中,接种疫苗组感染的基因型明显少于对照组(p = 0.035, p = 0.006)。队列1中入院儿童的情况并非如此(p = 0.478)。结论:RTS,S/AS02A在本试验中没有选择编码CSP c端区不同T细胞表位的基因型。在这两个队列中,与对照组相比,接种疫苗的儿童携带的寄生虫基因型的平均数量略有减少,但仅在无症状感染的儿童中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.

RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.

Objective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes.

Design: P. falciparum DNA from isolates collected during the trial was used for genotype studies.

Setting: The main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004.

Participants: Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection.

Outcome: Divergence of DNA sequence encoding the CSP T cell-epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined.

Results: We found no evidence that parasite genotypes from children in the RTS,S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 (survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, (p = 0.035, p = 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p = 0.478).

Conclusions: RTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信